Mayoly brings colchicine production back to France, securing domestic supply of an essential gout medication
Executive summary: Mayoly opened a colchicine manufacturing facility in Auxerre, France, on June 23, 2026. Domestic production ensures a stable supply of an essential gout medication for over 600,000 French patients and lessens dependence on imports.
Who is involved: Mayoly (French pharmaceutical lab), French healthcare system, patients requiring colchicine, and relevant regulatory authorities.
Likely next: The plant will ramp up output; stakeholders will monitor production volumes, pricing, and whether other firms follow similar reshoring initiatives.
The French laboratory Mayoly has inaugurated a new production line in Auxerre to manufacture colchicine, a drug prescribed to more than 600,000 patients in France and listed as a medicine of major therapeutic interest. This move reduces the country's reliance on foreign suppliers for a critical medication and aligns with broader efforts to strengthen pharmaceutical sovereignty. The inauguration highlights how reshoring can address supply‑chain vulnerabilities while supporting local manufacturing capacity.
What's next — scenarios
Sovereignty Premium (50%)
Mayoly captures increased market share and government procurement priority due to local manufacturing status.
- New French healthcare legislation prioritizing domestic producers
- Increase in government subsidies for reshoring initiatives
Operational Bottleneck (30%)
Higher cost of goods sold (COGS) due to European labor/compliance costs compared to global competitors.
- Reported production delays in Auxerre facility
- Rising energy costs in French industrial sectors
Global Competition Undercut (20%)
Low-cost generic imports disrupt Mayoly's margins despite the strategic domestic advantage.
- Significant price drops in imported colchicine alternatives
- New large-scale manufacturing plant openings in India or China
What to watch
- Mayoly Q3/Q4 manufacturing capacity utilization reports
- French Ministry of Health procurement contract awards (Next 90 days)
- Regional industrial energy price volatility in France (Next 30 days)
Timeline
- — Le laboratoire Mayoly relocalise en France la production de colchicine, un médicament essentiel contre la goutte (Le Monde — Économie)
Analysis — what this means
Likely next events
- Other French pharma firms may evaluate reshoring of essential medicines.
Sectors affected
- Pharmaceuticals
- Healthcare
- Manufacturing
Regulatory implications
- Reinforcement of the essential medicines list compliance.
- Ongoing monitoring of drug pricing and supply security.
Historical parallels
- Reshoring of active pharmaceutical ingredients during the COVID‑19 pandemic.
- France’s earlier move to bring paracetamol production back domestically.
- EU strategic autonomy initiatives targeting medicine supply chains.